Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Jhaveri on the Use of Trastuzumab Biosimilars in Breast Cancer

November 8th 2019

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.

Dr. Schwartzberg on the Use of Therapeutic Biosimilars in Breast Cancer

November 7th 2019

Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.

FDA Approves Sandoz's Pegfilgrastim Biosimilar

November 5th 2019

The FDA has approved the pegfilgrastim biosimilar LA-EP2006 (pegfilgrastim-bmez; Ziextenzo) as a treatment to decrease the incidence of infection, exhibited from febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer therapy that is associated with a clinically significant incidence of febrile neutropenia.

Dr. Vidal on Increasing Access to HER2-Targeted Therapy With Biosimilars

November 4th 2019

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.

Dr. Mato on Rituximab Biosimilars in CLL

November 1st 2019

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

Rituximab and Trastuzumab Biosimilars Shown to Have Economic Advantage Over Originators

November 1st 2019

Jacopo Giuliani, MD, discusses the analysis of the economic impact of biosimilars in breast cancer and follicular lymphoma.

Dr. Robson Discusses the Driving Force Behind Biosimilar Use in Oncology

October 29th 2019

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the driving force behind biosimilar use in oncology.

Former FDA Commissioner Scott Gottlieb Forecasts Future of Biosimilars

October 27th 2019

Scott Gottlieb, MD, discusses facets of biosimilar development as well as commercial and policy changes that could have the greatest impact on the use of these products in the field of oncology.

Dr. Shah on the Trastuzumab Biosimilar in Gastric Cancer

October 24th 2019

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

October 23rd 2019

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

Dr. Preeshagul on Education for Biosimilars in Oncology

October 22nd 2019

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.

Dr. Offin on Potential Implications of Introducing Biosimilars Into Oncology

October 22nd 2019

Michael D. Offin, MD, discusses the potential implications of introducing biosimilars into the field of oncology.

Dr. Mato on the Use of Biosimilars in CLL

October 17th 2019

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

Dr. Wierda on Role of Rituximab Biosimilar in Evolving CLL Treatment Paradigm

October 14th 2019

William G. Wierda, MD, PhD, discusses the role of the rituximab biosimilar in the chronic lymphocytic leukemia treatment paradigm.

ESMO 2019 Showcases Biosimilar Equivalency Data

October 11th 2019

Findings from the 2019 ESMO Congress showcased that biosimilars for pegfilgrastim, filgrastim, bevacizumab, and trastuzumab demonstrated efficacy and safety equivalency with their reference counterparts in a number of malignancies.

Dr. Untch on the Expanding Use of Biosimilars

October 9th 2019

Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.

Trastuzumab Biosimilar May Alleviate Financial Toxicity in HER2+ Breast Cancer

October 2nd 2019

Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology.

Dr. Yardley on Integrating Biosimilars Into Breast Cancer Treatment

October 2nd 2019

Denise Yardley, MD, discusses the impact of biosimilars on breast cancer treatment.

Dr. Lyman on G-CSF Biosimilars and Potential Impact on the Market

October 1st 2019

Gary H. Lyman, MD, MPH, discusses granulocyte colony-stimulating factor biosimilars and their impact on the market.

Dr. McBride on Biosimilar Rituximab

September 27th 2019

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).